Results 81 to 90 of about 31,387 (227)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Drug Design, Development and Therapy, 2021
Mohamad Moussa,1 Athanasios Papatsoris,2 Mohamed Abou Chakra,1 Athanasios Dellis2,3 1Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon; 2 2nd Department of Urology, School of Medicine, Sismanoglio ...
Moussa M, Papatsoris A, Abou Chakra M, Dellis A   +3 more
doaj  

AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes

Clinical &Experimental Allergy, EarlyView.
ABSTRACT The AllergoOncology field brings together the study of allergic and cancer immune responses, having evolved from early epidemiological studies that reported inverse associations between allergies, IgE and cancer risk. Insights from studying allergic inflammation are revealing previously unappreciated immune mechanisms that confer protective ...
Jakub Zydron, Anishaa Balaji, Jitesh Chauhan, Jack Alder, Xinyi Chen, Anna M. F. Wiegman, Aurelie Poli, Joanna Jacków‐Malinowska, Jack Cheeseman, Daniel I. R. Spencer, James McDonnell, James Spicer, Alexandra J. McCraw, Sophia N. Karagiannis   +13 more
wiley   +1 more source

Clinical and Pathological Features of the Nested Subtype of Urothelial Carcinoma With Lymph Node Metastasis as the Initial Presentation: A Case Report

Clinical Pathology
The nested subtype of urothelial carcinoma (NS-UC), a rare and aggressive bladder cancer, mimics benign bladder lesions but behaves like high-grade urothelial carcinomas.
Wenhua Li, Ying Zhang, Baocheng Lu, Min Yi   +3 more
doaj   +1 more source

A minor high‐grade component in non‐invasive papillary urothelial carcinoma is not associated with a more indolent behaviour

Histopathology, EarlyView.
Non‐invasive papillary urothelial carcinomas with minor high‐grade component are not associated with a more indolent behavior and should likely be regarded as high‐grade carcinomas. Aims The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade ...
Mina S. Farag, Neda Oghbaei, Jaffar Hussain, André Lametti, Wassim Kassouf, Fadi Brimo   +5 more
wiley   +1 more source

Collision metastasis in a pelvic lymph node from urothelial and prostatic carcinoma: a rare case report and literature review

Frontiers in Oncology
Metastasis of both urothelial carcinoma and prostatic carcinoma to the same lymph node is extremely rare. We report a case of collision metastasis involving bladder urothelial carcinoma and prostatic adenocarcinoma in a 76-year-old male.
Xue-Dong Shi, Xue-Dong Shi, Qiong-Nan Shen, Li Wei, Li-Juan Chen, Hui-Fen Wang, Xu-Dong Zheng, Qi Ma, Qi Ma   +8 more
doaj   +1 more source

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

New England Journal of Medicine, 2019
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations.In this
Loriot, Y, Necchi, A, Park, SH, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, ST, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A, Siefker-Radtke, AO, BLC2001 Study Group   +21 more
openaire   +3 more sources

PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles – A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases

Histopathology, EarlyView.
PAX8 expression in urothelial carcinoma was investigated in 101 consecutive transurethral resections of the urinary bladder. PAX8 was positive in 10% of cases, with targeted molecular testing of these cases revealing universal TERT promoter mutations and frequent alterations in TSC1, NOTCH1 and WT1. Aims PAX8 immunohistochemistry (IHC) is often used to
Sarah Mae Lammert, Wendy Luo, Allen C Zhu, Peng Wang, Tatjana Antic, Jung Woo Kwon   +5 more
wiley   +1 more source

Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports

IJU Case Reports
Introduction Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end‐stage renal disease requiring hemodialysis.
Shintaro Mori, Tomohiro Matsuo, Hiroyuki Honda, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura   +7 more
doaj   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

BJU International, EarlyView.
Kevin G. Keane, Richard Gauci, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Andrisha‐Jade Inderjeeth, Ian D. Davis, Jayne Lim, Andrew Redfern, Dickon Hayne   +9 more
wiley   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source